These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

270 related items for PubMed ID: 10537166

  • 1. Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice.
    Asa SL, Kelly MA, Grandy DK, Low MJ.
    Endocrinology; 1999 Nov; 140(11):5348-55. PubMed ID: 10537166
    [Abstract] [Full Text] [Related]

  • 2. Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice.
    Hentges ST, Low MJ.
    Endocrinology; 2002 Dec; 143(12):4536-43. PubMed ID: 12446580
    [Abstract] [Full Text] [Related]

  • 3. Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms.
    Schuff KG, Hentges ST, Kelly MA, Binart N, Kelly PA, Iuvone PM, Asa SL, Low MJ.
    J Clin Invest; 2002 Oct; 110(7):973-81. PubMed ID: 12370275
    [Abstract] [Full Text] [Related]

  • 4. Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas.
    McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE.
    Endocrinology; 1995 Oct; 136(10):4479-88. PubMed ID: 7664668
    [Abstract] [Full Text] [Related]

  • 5. Pituitary morphology of transgenic mice expressing bovine growth hormone.
    Stefaneanu L, Kovacs K, Bartke A, Mayerhofer A, Wagner TE.
    Lab Invest; 1993 May; 68(5):584-91. PubMed ID: 8388524
    [Abstract] [Full Text] [Related]

  • 6. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients.
    Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, Patey M, Mazucca M, Decullier E, Vergès B, Chabre O, Calender A, Groupe d'études des Tumeurs Endocrines.
    Am J Surg Pathol; 2008 Apr; 32(4):534-43. PubMed ID: 18300794
    [Abstract] [Full Text] [Related]

  • 7. Fibroblast growth factor-2 in hyperplastic pituitaries of D2R knockout female mice.
    Cristina C, Díaz-Torga G, Góngora A, Guida MC, Perez-Millán MI, Baldi A, Becu-Villalobos D.
    Am J Physiol Endocrinol Metab; 2007 Nov; 293(5):E1341-51. PubMed ID: 17848635
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas.
    Luque GM, Perez-Millán MI, Ornstein AM, Cristina C, Becu-Villalobos D.
    J Pharmacol Exp Ther; 2011 Jun; 337(3):766-74. PubMed ID: 21406548
    [Abstract] [Full Text] [Related]

  • 9. PTTG expression in different experimental and human prolactinomas in relation to dopaminergic control of lactotropes.
    Cristina C, Díaz-Torga GS, Goya RG, Kakar SS, Perez-Millán MI, Passos VQ, Giannella-Neto D, Bronstein MD, Becu-Villalobos D.
    Mol Cancer; 2007 Jan 12; 6():4. PubMed ID: 17222350
    [Abstract] [Full Text] [Related]

  • 10. Pituitary enlargement with suprasellar extension in functional hyperprolactinemia due to lactotroph hyperplasia: a pseudotumoral disease.
    Peillon F, Dupuy M, Li JY, Kujas M, Vincens M, Mowszowicz I, Derome P.
    J Clin Endocrinol Metab; 1991 Nov 12; 73(5):1008-15. PubMed ID: 1939514
    [Abstract] [Full Text] [Related]

  • 11. Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia.
    Radl D, De Mei C, Chen E, Lee H, Borrelli E.
    Mol Endocrinol; 2013 Jun 12; 27(6):953-65. PubMed ID: 23608643
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pituitary gland in hypothyroidism. Histologic and immunocytologic study.
    Scheithauer BW, Kovacs K, Randall RV, Ryan N.
    Arch Pathol Lab Med; 1985 Jun 12; 109(6):499-504. PubMed ID: 2986571
    [Abstract] [Full Text] [Related]

  • 15. Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma.
    Cristina C, García-Tornadú I, Díaz-Torga G, Rubinstein M, Low MJ, Becú-Villalobos D.
    Front Horm Res; 2006 Jun 12; 35():50-63. PubMed ID: 16809922
    [Abstract] [Full Text] [Related]

  • 16. Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice.
    Kelly MA, Rubinstein M, Asa SL, Zhang G, Saez C, Bunzow JR, Allen RG, Hnasko R, Ben-Jonathan N, Grandy DK, Low MJ.
    Neuron; 1997 Jul 12; 19(1):103-13. PubMed ID: 9247267
    [Abstract] [Full Text] [Related]

  • 17. The effect of GHRH on somatotrope hyperplasia and tumor formation in the presence and absence of GH signaling.
    Kineman RD, Teixeira LT, Amargo GV, Coschigano KT, Kopchick JJ, Frohman LA.
    Endocrinology; 2001 Sep 12; 142(9):3764-73. PubMed ID: 11517152
    [Abstract] [Full Text] [Related]

  • 18. Leukemia inhibitory factor regulates prolactin secretion in prolactinoma and lactotroph cells.
    Ben-Shlomo A, Miklovsky I, Ren SG, Yong WH, Heaney AP, Culler MD, Melmed S.
    J Clin Endocrinol Metab; 2003 Feb 12; 88(2):858-63. PubMed ID: 12574225
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.